Avinger Inc. (NASDAQ: AVGR) stock declined by 2.56% at the last close while the AVGR stock price gains by 9.65% in the pre-market trading session. Avinger is a medical device business in the commercial stage that is developing the very first image-guided, catheter-based device for the diagnosis and management of diseases with Peripheral Artery Disease (PAD).
>> 7 Top Picks for the Post-Pandemic Economy <<
What is happening?
At two significant vascular conferences in Germany, Avinger announced key opinion leader (KOL) presentations using AVGR’s Lumivascular technology: the annual German CLI Congress and the Essen Vascular Conference.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
At the annual Critical Limb Ischemia (CLI) Congress in Germany, Dr. Arne Schwindt who is a vascular surgeon from St. Franziskus Hospital Münster in Germany delivered a presentation on Avinger’s Lumivascular technology. The CLI Congress has a comprehensive teaching agenda focused on preventing amputations and treating PAD patients. The presentation, named “OCT guided atherectomy,” included case studies of Pantheris patients to demonstrate the benefits of onboard OCT imaging.
Traditional therapeutic procedures such as ballooning and stenting have their benefits, according to Dr. Schwindt, but between 10% and 40% of patients treated with a stent have restenosis and recurrence of symptoms within the first year. Options are restricted if these therapeutic failures result in CLI. Pantheris’ lumivascular atherectomy gives doctors the ability to clear clogged stents under visual supervision and help patients recover from CLI. They are extremely happy with the post-treatment clinical findings, and he believes that patients will benefit from this therapy modality, which uses Avinger’s on-board imaging atherectomy equipment.
>> 7 Top Picks for the Post-Pandemic Economy <<
Furthermore,
Dr. Schwindt also presented a talk about Avinger technology at the Essen Vascular Conference earlier this month. Essen Vascular is a regional meeting that attracts about 300 people every year. The meeting is focused on PAD therapies, both conservative and interventional, as well as AV-shunts. “Atherectomy of the common femoral artery – What’s Possible Interventionally?” was the topic of the presentation, which centered on patients who were treated with Avinger’s image-guided devices.
